Kliniken & Institute … Kliniken Zentrum für Innere… Innere Medizin V:… Willkommen 4th CELL THERAPY…


November 6 & 7, 2020


Dear colleagues,

Since our last Cell Therapy Symposium only one year has elapsed. Within this short period of time, tremendous progress has been made in our clinic regarding CAR T cells therapy: more than 70 patients have received this innovative treatment at our center. In Europe more than 700 patients have been treated for acute leukemia, Non-Hodgkin lymphoma and myeloma with remarkable success. Therefore the therapeutical algorithms for the treatment of these diseases need to be revisited. Moreover, the safe management of cytokine release syndrome, neurotoxicity and prolonged cytopenia will be highlighted in this symposium. In addition, novel targets and preclinical research for further development of immunogene therapy will be discussed.

We are very proud to present a panel of speakers from the major CAR T cell centers in Germany, France and Spain to give an update of the current status. Also, we are very excited that we could win Prof. Gottschalk, St. Jude Hospital, Memphis/USA to give a key note lecture on his impressive achievements in the field of immuno cell therapy.

We are looking forward to welcoming you to our symposium.

With very warm regards from Heidelberg

Michael Schmitt, Carsten Müller-Tidow, Peter Dreger


The participation is free of charge.
The meeting has been certified from the Landesärztekammer and CME points are granted.


Day 1

12:00 Registration

Welcome address
Carsten Müller-Tidow

Carsten Müller-Tidow / Peter Dreger

13:10 Current Status report of the Heidelberg HD-CAR-1-Trial
Michael Schmitt
13:30 2 years of experience with commercial CARTs in Heidelberg: Lessons to be learned
Peter Dreger

CD70 and CD96 as novel targets for CAR T cell therapy in myeloid disease
Tim Sauer

14:10 Transposon driven CAR T cell therapy
Michael Hudecek
14:30 BCMA-CAR production in a closed system
Armin Rehm
14:50 From DLIs to allo-CARs
Hans-Jochem Kolb

Coffee break

Anthony D. Ho / Andreas Kulozik

15:40 Practical side effect management in CAR-T cell therapy
Maria-Luisa Schuber
16:00 EBMT Registry for CAR T cells
Christian Chabannon
16:20 Leukapheresis for CARs – what is important for the proper preparation of the patient?
Anita Schmitt
16:40 Regulatory issues with genomic editing
Klaus Cichutek / PEI Langen
17:00 Gene therapy for thalassemia patients
Andreas Kulozik
17:20 KEY NOTE: CAR T cell therapy for solid tumors: bright future or dark reality?
Stephen Gottschalk / Jude, Memphis, USA

Day 2

Eva-Maria Wagner-Drouet / MarionSubklewe
09:00 CMV reactivation after transplantation of stem cells or CARs
Patrick Derigs
09:10 Home care setting for foscavir application
E. Wagner-Drouet, Uni Mainz
09:30 Experience with home-brewn CARs in Barcelona
Manel Juan, Uni Barcelona
09:50 Pathophysiology of neurotoxicity CAR-T cell therapy
Marion Subklewe, LMU München
10:10 Finetuning CD19 CART indications –conclusions from prognostic factor analyses
Francis Ayuk, UKE Hamburg
10:30 Novel CAR constructs for multiple myeloma
Uta Höpken, MDC Berlin

Coffee break

Anita Schmitt / Tim Sauer

11:20 Endothelial biomarkers and CART toxicity
Thomas Luft
11:40 Impact of CARs on the microbiome
Christoph Stein-Thöringer
12:00 Lymphoma relapse after CARs –strategies for prevention and treatment?
Sascha Dietrich
12:20 PRAME-TCR therapy of patients with AML/MDS or myeloma
Simone Thomas, Uni Regensburg
12:40 Summary
Michael Schmitt



Prof. Dr. Francis Ayuketang Ayuk, UKE Hamburg
Prof. Dr. Christian Chabannon, Aix-Marseille Universität, Frankreich
Prof. Dr. Klaus Cichutek, Paul-Ehrlich-Institut, Langen
Prof. Stephen Gottschalk, St. Jude Hospital, Memphis, USA
Univ. Prof. Dr. Michael Hudecek, Universitätsklinikum Würzburg
PD Dr. Uta Höpken, MDC Max-Delbrück-Centrum, Berlin
Prof. Dr. Manel Juan, SJD Barcelona Children's Hospital, Spanien
Prof. em. Dr. Hans-Jochem Kolb, München
Dr. Armin Rehm, MDC Max-Delbrück-Centrum, Berlin
Dr. Christoph Stein-Thöringer, DKFZ, Heidelberg
Prof. Dr. Marion Subklewe, LMU München
PD Dr. Simone Thomas, Universitätsklinikum Regensburg
Dr. Eva-Maria Wagner-Drouet, Universitätsmedizin Mainz
Prof. Dr. Andreas Kulozik, PhD, Pädiatrische Onkologie, Zentrum für Kinder- und Jugendmedizin, Universitätsklinikum Heidelberg

Medizinische Klinik V (Hämatologie, Onkologie und Rheumatologie), Universitätsklinikum Heidelberg:
Dr. Patrick Derigs
PD Dr. Sascha Dietrich
Prof. Dr. Peter Dreger
Prof. Dr. Dr. Thomas Luft, PhD
Prof. Dr. Carsten Müller-Tidow
Dr. Tim Sauer
Dr. Maria-Luisa Schubert
PD Dr. Anita Schmitt
Prof. Dr. Michael Schmitt


GILEAD Sciences GmbH
Novartis Pharma GmbH
bluebird bio (Germany) GmbH
Cellgenix GmbH
Celgene GmbH
Clinigen Healthcare Germany
Janssen-Cilag GmbH
MSD Sharp & Dohme GmbH
Takeda Pharma Vertrieb GmbH & Co. KG
Roche Pharma AG
Hexal AG
Miltenyi Biotec GmbH



Medical Clinic, Grand Auditorium
Im Neuenheimer Feld 410
69120 Heidelberg


Universitätsklinikum Heidelberg
Medizinische Klinik V / Zelluläre Immuntherapie
Im Neuenheimer Feld 410, 69120 Heidelberg

Contact person: Regina Hollenbach
Tel.: 06221 56-7989
E-Mail: Regina.Hollenbach(at)med.uni-heidelberg.de